This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Nov 22;316(20):2152.

doi: 10.1001/jama.2016.16292.

Cost-effectiveness of PCSK9 Inhibitor Therapy-Reply

Dhruv S Kazi¹, Andrew E Moran², Kirsten Bibbins-Domingo¹

Affiliations

Affiliations

¹ Department of Medicine, University of California, San Francisco.
² College of Physicians and Surgeons, Columbia University, New York, New York.

PMID: 27893125
DOI: 10.1001/jama.2016.16292

Comment

Cost-effectiveness of PCSK9 Inhibitor Therapy-Reply

Dhruv S Kazi et al. JAMA. 2016.

. 2016 Nov 22;316(20):2152.

doi: 10.1001/jama.2016.16292.

Authors

Dhruv S Kazi¹, Andrew E Moran², Kirsten Bibbins-Domingo¹

Affiliations

¹ Department of Medicine, University of California, San Francisco.
² College of Physicians and Surgeons, Columbia University, New York, New York.

PMID: 27893125
DOI: 10.1001/jama.2016.16292

No abstract available

PubMed Disclaimer

Comment on

Cost-effectiveness of PCSK9 Inhibitor Therapy.
Mastey V, Johnstone BM. Mastey V, et al. JAMA. 2016 Nov 22;316(20):2151-2152. doi: 10.1001/jama.2016.16286. JAMA. 2016. PMID: 27893122 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal